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Background: Protocols utilizing high-sensitivity cardiac troponin (hs-cTn) assays for the evaluation of suspected
acute coronary syndrome (ACS) in the emergency department (ED) have been gaining popularity across the US
and the world. These protocols more rapidly rule-out ACS and more accurately identify the presence of acute
myocardial injury. At this time, few randomized trials have evaluated the safety and operational impact of these
assays, resulting in limited evidence to guide the use and implementation of hs-cTn in the ED.
Objective: The main study objective is to test the effectiveness of a rapid ACS rule-out pathway using hs-cTnI in
safely discharging patients from the ED for whom clinical suspicion for ACS exists.
Design: This prospective, implementation trial (n = 11,070) will utilize a stepped wedge cluster randomized trial
design. The design will allow for all participating sites to capture benefit from the implementation of the hs-cTnI
pathway while providing data evaluating the effectiveness in providing safe and rapid evaluation of patients with
clinical suspicion for ACS.
Summary: Demonstrating that clinical pathways using hs-cTnI can be effectively implemented to rapidly rule-out
ACS while conserving costly hospital resources has significant implications for the care of patients with possible
acute cardiac conditions in EDs across the US.
Clinicaltrials.gov identifier: NCT04488913.

1. Introduction
Cardiovascular disease is the leading cause of mortality in the United
States [1]. Amongst patients with acute coronary syndrome (ACS),
cardiac biomarkers are critical in detecting acute myocardial infarction
(AMI). Newly approved for use in the US high sensitivity cardiac
troponin (hs-cTn) biomarkers are increasingly being used in emergency
departments (ED) to rapidly rule out ACS with the promise of expediting
patient disposition while reducing hospital resource utilization [2–9].
In an effort to more efficiently diagnose and triage patients with
possible ACS, Henry Ford Health System (HFHS) is implementing the
Beckman Coulter Access hs-cTnI assay across 9 EDs. Paired with the

introduction of the new hs-cTnI assay, we have developed a new clinical
decision-making pathway, titled “Rapid Acute Coronary Syndrome
Exclusion using the Beckman Coulter Access high-sensitivity I Troponin”
(RACE-IT), to quickly identify patients with AMI and rule-out low risk
patients utilizing hs-cTnI values in combination with a HEAR score [10,
11].
Prior studies have established the safety of such an approach,
including the RAPID-TnT study which utilized a 0/1-h hs-cTnT protocol
and had a negative predictive value of 99.6% for 30-day death or AMI
[12]. Additionally, this study showed the hs-cTnT approach was
non-inferior to standard care, associated with a shorter ED length of
stay, and patients were more likely to be discharged from the ED [12].
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They were also less likely to undergo functional cardiac testing.
However, while there is significant promise for hs-cTn protocols to
reduce healthcare utilization while preserving patient safety, interna
tional trials in health care settings other than the US have suggested that
adherence can be difficult to achieve with unguided implementation of
such protocols [5,12–15]. To ensure both effective implementation and
to study the operational impact, HFHS will utilize a modified stepped
wedge cluster design to evaluate the new RACE-IT pathway.
This implementation trial will directly evaluate the primary outcome
of safe discharge from the ED and multiple secondary endpoints such as
overall patient safety and cost-effectiveness [14]. Additionally, assess
ment of outcomes in patients with minimally elevated hs-cTnI values
who require further testing will provide rich data for phenotypic anal
ysis, allowing us to evaluate specific patient phenotypes based on their
hs-cTnI values. Publication of these results will provide important data
to other health systems considering similar implementation and will
help guide clinical decision making.

that benefit from any participating sites. We have designed the trial in
concordance with the most recent CONSORT recommendations for
modified stepped wedge cluster randomized trials [16]. Each of the sites
will have three phases as detailed in Fig. 1, which include current SOC
with data collection, an implementation phase where the RACE-IT
pathway is started but no data are collected, and the RACE-IT
pathway where it is active and data are being gathered. The planned
implementation will take place over seven months with each phase
lasting three weeks and each site randomly being allocated to enter the
treatment condition at different time periods. We will trace rates of
adherence to the RACE-IT pathway for each cluster over the course of
the trial. Table 1 details inclusion and exclusion criteria for study par
ticipants. The planned sample size is 11,070 patients. Data analysis is
expected to be completed within one year.
2.3. Setting
HFHS has nine associated EDs which will serve as sites for this study.
These include Henry Ford Main, a quaternary care, level-1 trauma center
in the heart of Detroit that cares for a primarily urban population, in
addition to four suburban community hospital EDs (Allegiance, West
Bloomfield, Macomb, and Wyandotte) and four free-standing EDs in
metro-Detroit (Fairlane, Sterling Heights, Brownstown, and Cottage).

2. Methods and analysis
2.1. Main objectives and hypotheses
The primary objective of this study is to compare safe ED discharge to
home rates among patients receiving standard of care (SOC) evaluation
for ACS and the new RACE-IT pathway. We hypothesize that patients
evaluated under the new pathway who have ED hs-cTnI values ≤ 18 ng/
L will have higher rates of safe discharge home. A safe discharge con
stitutes a discharge to home in which a patient has no all-cause death or
AMI within 30 days of their ED presentation.
Our main secondary objectives are to assess AMI and death rates for
one year after each patient’s initial encounter, to create a registry of
patients with quantifiable hs-cTnI values ≤ 18 ng/L who are placed in
observation, and to assess the cost-effectiveness of the RACE-IT
pathway. This registry will allow for exploratory analysis of pheno
types that may confer low risk for death and MI at 30-days. We hy
pothesize that the implementation of the RACE-IT pathway will result in
reduced hospital resource utilization and associated operational costs.

2.4. Intervention arm: RACE-IT pathway
The primary intervention, the implementation of the RACE-IT
pathway, will be rolled out in phases according to the modified step
ped wedge cluster randomized trial design. This pathway is substanti
vely different from the current SOC pathway used at all participating
EDs. Appendix A details the RACE-IT pathway. All patients with a first
hs-cTnI value < 4 ng/L will be deemed very low risk and, if appropriate,
eligible for immediate discharge. Patients with an initial value equal to
4 ng/L will have repeat testing in 1 h and if the increase is < 4 ng/L
Table 1
Eligibility criteria.
Inclusion Criteria:
● Age ≥18 years old
● Clinician suspicion for ACS triggering baseline ECG and cardiac troponin testing
Exclusion Criteria:
● ST-segment Myocardial Infarction leading to immediate reperfusion therapy
● Any ED-drawn hs-cTnI value > 99th percentile
● Clear traumatic cause for symptoms (e.g., direct chest wall trauma)
● A transfer from another facility
● Primary residence outside the state of Michigan
● Previous inclusion in the study
● Enrolled in hospice

2.2. Study design
This is a pragmatic, implementation study testing the implications of
a rapid evaluation pathway for suspected ACS using a hs-cTnI assay. A
modified stepped wedge cluster design will take a phased approach to
implementation across all nine HFHS EDs. This approach will result in
all sites being exposed to both the control and novel protocol (SOC vs
RACE-IT pathway). This design was chosen for this study because the
proposed RACE-IT pathway has presumed benefit and does not withhold

Fig. 1. Stepped Implementation Design Matrix. Each segment represents a 3-week period. Blue segments indicate enrollment under the standard of care protocol,
and orange cells indicate enrollment under RACE-IT pathway. Green cells indicate 3-week implementation periods for clinician education and time to accommodate
practice change, during which patient enrollment does not occur. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web
version of this article.)
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Table 2 will be collected through electronic health record (EPIC, Verona,
WI) report functions and standardized chart review. Prior to study
initiation, a data dictionary will be finalized, and team members will be
trained on any required data abstraction. Data to be collected will
include patient demographics, laboratory results (CBC, BNP, D-dimer,
and hs-cTnI), ED and hospital length of stay, disposition, primary and
secondary diagnoses, and for those patients requiring observation or
admission, results of further diagnostic testing (cardiac stress testing,
echocardiography, cardiac CT, cardiac MRI, cardiac catheterization). In
addition to health outcomes data, we will also collect operational data to
evaluate the effect of the RACE-IT pathway on throughput, resource
utilization, and cost effectiveness. The data to be collected include
patient-level reimbursement data from each encounter, utilization of
diagnostic testing, and consultation with in-hospital cardiology services.
For outcome assessment, we will utilize Michigan’s statewide health
information exchange (MiHIN) to identify patients with suspected AMI
or death. This MiHIN provides a comprehensive assessment of any
healthcare encounter at an ED or hospital throughout Michigan and
provides data directly to HFHS secure data warehouses. If a patient has
no encounters within the MiHIN over 30 days after their index ED
encounter, we will consider that patient to have no event during that
time period. There is the possibility of incomplete reporting or events
that occur out of state, though we do not anticipate a bias in outcome
assessment between patients managed with SOC and the RACE-IT
pathway due to this limitation.
For patients who have an encounter identified on the MiHIN that has
no cardiovascular related diagnoses, we will also consider that patient to
have no AMI. For patients that have a cardiovascular related diagnosis,
our team will supplement the MiHIN information with any additional
information available in the electronic health record. We will make this
information available in a de-identified manner for an adjudication
team. The adjudication team (described below) will use this data to
determine if a patient had an AMI or death (cardiac or non-cardiac).
Finally, we will supplement the above processes with the Centers for
Disease Control and Prevention national death index to determine if any
death occurred in the study population outside available records.
While AMI and death are the primary outcome considerations, we
will also track all revascularization procedures (PCI or CABG) and any
rehospitalization related to cardiovascular disease over 30 days. Car
diovascular rehospitalization includes readmission for coronary revas
cularization, peripheral artery disease, cerebrovascular accidents,
congestive cardiac failure without AMI, and atrial and ventricular ar
rhythmias. Lastly, we will continue to track these outcomes through
diagnostic codes in MiHIN out to one year following each patient’s
initial encounter.
In order to accurately determine the primary outcome (AMI or
death), two independent adjudicators will review each case, and if there
is disagreement a third adjudicator will review the case as well. All
adjudicating physicians will be board-certified cardiologists or emer
gency medicine physicians. The diagnosis of AMI will be determined it
in accordance with the fourth Universal Definition after review of all
available 30 day or one year clinical data and the serial individual hscTnI measurements utilized during the index or subsequent visit [18].
In the event that adjudicating physicians deem that too much data is
missing to make an adequate determination for AMI, the outcome will
be coded as unknown and incorporated into a sensitivity analysis.

(delta <4 ng/L), those patients will also be eligible for discharge home.
Patients with an initial hs-cTnI ≥5 ng/L and ≤18 ng/L will receive
repeat testing at one and 3 h, and if all levels are ≤18 ng/L, the HEAR
score (also called the modified HEART score or HEART pathway) [11,
17] will be used to make a disposition decision. Patients in the prior
group who have a HEAR score of <4 will be eligible for discharge home
while observation will be recommended to these patients who have a
HEAR score of ≥4 [11]. The management of patients with hs-cTnI >99th
percentile upper reference limit (18 ng/L) is no different within the
RACE-IT pathway compared to SOC. A figure demonstrating the full
pathway is available in the supplementary material (Appendix A).
2.5. Control arm: SOC pathway
The existing SOC protocol includes evaluation of suspected ACS with
0- and 3-h hs-cTnI evaluation and use of the 99th percentile as the upper
reference limit. The lab reports actual values above the 99th percentile
(18 ng/L), but reports measurements below the 99th percentile as < “18
ng/L”. Clinicians can discharge patients from the ED if hs-cTn values do
not exceed the 99th percentile with a HEAR score <4. Patients with
clinical concern for possible ACS and a HEAR score ≥4 are often placed
in observation care in the hospital. Patients with very high suspicion for
unstable angina or AMI, may be directly admitted to a cardiology unit.
Physicians always can place patients in observation if the patients have
low HEAR scores but there is still a residual concern for ACS. Patients
with rising hs-cTnI levels above the 99th percentile who are concerning
for AMI are admitted to a cardiology floor.
2.6. Screening and enrollment
Patients that meet the inclusion criteria will be identified through the
electronic health record (EHR) across all 9 HFHS EDs. After exclusion
criteria are applied, a master registry will be created of eligible study
patients. A log of ineligible patients for standardized reporting will be
maintained, including reasons for exclusion and other demographic in
formation. The volume of eligible ED patients over the course of the
planned study period may exceed our necessary sample size. Data
collection will include all eligible patients over the study period. We will
perform complete data collection on the eligible population for analysis.
Further description of sample size planning is described below. The
sponsoring institutional review board has granted waiver of consent for
the trial.
2.7. Data collection and outcome measures
REDCap (Nashville, TN), a secure data management tool, will be
used for data collection and management. Data elements outlined in
Table 2
Core data elements.
Demographics

Age, Sex, Race, Ethnicity

ED Measures

Triage time, blood draw time, length of stay, disposition,
BP, HR, BMI, diagnoses
HTN, DM, dyslipidemia, tobacco use, CAD, prior MI, PVOD,
CKD, CHF, revascularization
All hs-cTnI values, BNP, CBC, metabolic profile, d-dimer,
CT chest
HEAR score, recorded time of symptom onset, ASCVD score
Echo, Stress test, heart cath, CT coronary results, cardiac
MRI, cardiology consultation, diagnoses, length of stay
Length of stay, Revascularization (PCI or CABG), diagnoses
Death (cardiac or non-cardiac), AMI, hospital payments
received (patient level reimbursement), rehospitalization
for cardiovascular disease, non-cardiac diagnoses
Death (cardiac or non-cardiac), AMI, hospital payments
received (patient level reimbursement), rehospitalization
for cardiovascular disease

Risk Factors
Lab and Imaging
Historical Factors
Observation Stay
Evaluation
Hospital Factors
Outcomes within 30Days
Outcomes, 1-year

2.8. Study funding
Beckman Coulter has funded an investigator-initiated grant to sup
port this work.
2.9. Sample size determination
Sample size and power have both been determined based on guide
lines for stepped wedge cluster randomized trials using PASS 2019
3
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rule using clinical characteristics, HEAR score, and different cutoffs with
the baseline hs-cTn values and delta values. This analysis will implement
random forest techniques and could determine a clinical decision rule
with superior performance using different hs-cTn cut-offs than are
currently in clinical use. The primary outcome for this analysis will be
30-day rates of AMI or death.

(NCSS, Kaysville, UT). Intraclass correlation coefficient (ICC) is esti
mated to be 0.05, and we will have nine steps with one cluster each. We
assume the following additional variables: SOC patients will have a safe
discharge rate of 40% based on prior operational data and RACE-IT
patients will have a rate of 45%. Assuming variable cluster size (coef
ficient of variance 0.4), an alpha of 0.05, and 90% power, we estimate
that a sample size of 11,070 patients will need to be evaluated to test our
primary endpoint. While allowing for variable cluster sizes, this sample
size equates to an average of 123 patients per cluster per time period (90
total 3-week block time periods). We will include all patients in each
time period over the course of the trial, and we anticipate exceeding the
requisite sample size.

2.10.3. Health economics analysis
In addition to the clinical effectiveness of RACE-IT, we propose to
evaluate the economic justification of the pathway compared to SOC
protocol. In fact, we hypothesize the RACE-IT will result in a lower
overall cost of treatment, capitalizing on avoided admissions, reduced
length of stay, fewer resources used, and lower rate of AMI, death,
readmission, and overall hospital charges at 30 days.
To assess the cost-effectiveness of the RACE-IT pathway compared to
the SOC protocol, we will measure resource utilization, length of stay,
rates of admission, AMI, death, and hospital charges at 30 days to
compare operational cost and quality associated with patient care under
both protocols. Resource utilization will include detailed CPT billing
code information on all performed cardiovascular procedures both in
the ED and hospital setting, regardless of whether a patient is discharged
home from the ED or brought into observation or inpatient care.
Within-trial incremental costs associated with the SOC and RACE-IT
protocols will be estimated using hospital reported reimbursements
from insurers received for ED and inpatient hospital costs. Incremental
cost effectiveness will be defined with respect to the primary clinical
outcome, either as avoided adverse outcomes or improved patient out
comes [20]. The length of study does not allow a trial-based evaluation
of the quality-adjusted life years (QALYs); however, we will use the
incidence of AMI and other adverse outcomes combined with estimates
from literature to compute the expected QALY for rate of occurrence of
such outcomes. In addition to linear multivariate and two-part estima
tion models, we will also estimate mean difference in cost and effects
using nonparametric bootstrapping techniques with patient-level data to
account for uncertainty due to sampling variation in cost-effectiveness.
We will incorporate relevant data sources and literature to extrapolate
the longer-term costs and benefits derived from observed differences in
cardiovascular events to generate full estimates of the cost-effectiveness
of the new protocol [21,22].

2.10. Methods of statistical analysis
2.10.1. Primary analysis
The analysis will utilize generalized mixed models to evaluate the
effect of RACE-IT to account for the clustering of patients within centers,
where each center will be included as a random effect [19]. The primary
analysis will adjust for the possible baseline variables listed in Table 2
which are known to affect cardiovascular outcomes. We will include a
time-dependent variable to denote the change from SOC to the RACE-IT
protocol phase as determined by the stepped wedge design and include
time as an independent variable in all models. The effect of imple
mentation of the RACE-IT protocol will be reported as an odds ratio with
its 95% confidence interval (CI). The statistical nature of missing data
will be assessed, and sensitivity analysis will be performed to analyze the
impact of missing data on results in order to propose the most appro
priate imputation method. Sensitivity analyses include an evaluation to
assume the worst unknown primary outcome for the patient by the
adjudication committee to in fact have AMI or death within 30-days. To
account for the potential of significant convergence of the SOC and
RACE-IT pathways for patients with an initial hs-cTn value of 6–18 ng/L,
we will report the proportion of patients with hs-cTn ≤5 ng/L in total
and stratified by HEAR <4 or ≥4. The primary analysis will be per
formed according to the intention-to-treat principle. All analyses will
use SAS version 9.4 (SAS Institute Inc., Cary, NC). All tests will be
two-sided with p-value < 0.05 as statistical significance.
2.10.2. Secondary analyses
We will also compare 30 day rates of AMI or death (binary outcome)
among patients discharged home or placed in observation in both co
horts. We will use generalized mixed models to evaluate the effect of
RACE-IT to account for the clustering of patients within centers, where
center will be included as a random effect.
Using outcome assessment to one year, we will also compare survival
curves between patients in the SOC or RACE-IT cohorts. If patients have
no AMI or death, they will be censored one year following their index
encounter. If they have AMI or death, they will be censored at the time of
that initial event. Survival curves will additionally look at rates of
revascularization (CABG or PCI) and rehospitalization for cardiovascu
lar disease. The time-to-event curves will be calculated with the KaplanMeier method and compared, when appropriate, using marginal Cox
proportional hazards regression model. Multilevel and multivariable
Cox regression models are considered using the same patient covariates
as the primary analysis and incorporating exposure to SOC or the RACEIT pathway.
We will perform exploratory analyses on patients placed in obser
vation both under SOC and RACE-IT. We will compare utilization of
stress tests, cardiology consultation, coronary CTA, coronary angiog
raphy, and PCI. We also will perform sensitivity analyses to determine if
phenotypes based on HEAR score, age, gender, race, and different hscTnI value/delta cut-offs are associated with low rates of AMI or death
at 30 days and one year. We will use a similar mixed model for these
analyses as described for the primary outcome above.
We also plan analysis to derive and validate a new clinical decision

3. Ethical considerations
The proposed study will be taking place during a change in routine
medical care and all participating sites will move to the RACE-IT
pathway during the study period. As such, the protocol change falls
within an overall quality improvement project and does not constitute a
research intervention. Hence, the anticipated risk for patients partici
pating in data collection during this transition in clinical care is pri
marily limited to a loss of confidentiality. Data collection through secure
servers will safeguard against this threat. Potential benefits include
earlier discharge from the ED, avoidance of costly observation stays or
hospital admission, and possible reduction of invasive cardiac testing.
4. Discussion
This trial comparing the RACE-IT pathway utilizing the hs-cTnI,
compared to SOC with conventional cTn evaluation (only reporting
values > 99th%), will provide essential data regarding operational im
pacts and safety of hs-cTnI implementation. The aim for this study is to
form a workflow that gives ED physicians the ability to quickly deter
mine which patients will require admission for further evaluation of ACS
versus those that can be safely discharged home based on hs-cTnI values
and risk stratification with HEAR scores. Should the data reveal an
effective, safe, and cost-effective algorithm, the implications on
decreased ED length of stay, patient morbidity, and systems operations
could be significant. The study results will have implications for EDs
4
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well beyond HFHS as many ED sites around the world are in the process
of implementing hs-cTn protocols.
The modified stepped wedge cluster design with the phased
approach for implementation will allow for streamlined integration of
the proposed RACE-IT pathway without restricting benefits from any
patient that visits an ED with suspected ACS. The current timeline for
implementation as well as data analysis is to be completed within one
year. The nine participating EDs altogether care for approximately
464,000 patient encounters each year. Building a trial in a health system
that evaluates large volumes of patients presenting with possible ACS
provides an organic environment within which to test the algorithm
without significant concern for meeting the goal sample size of 11,070.
The RACE-IT pathway uses clinical risk stratification with the HEAR
score (HEART score without troponin component [11]) in addition to
hs-cTnI testing to determine which patients with suspected ACS and
quantifiable hs-cTnI values below the 99th percentile should be placed
in observation for further testing or sent home. Previous studies have
shown that by including a clinical risk score, the safety involving the
hs-cTn threshold at 99th percentile is greatly improved for ruling in and
ruling out the need for further evaluation [3,23]. Additionally, this trial
is unique as it will also look at quantifiable hs-cTnI values that fall below
the 99th percentile (≤18 ng/L) to allow for exploratory analysis of
phenotypes that may confer low risk. Altogether, this clinical trial has
the ability to create a novel clinical workflow regarding ACS using the
hs-cTnI assay along with the HEAR score.
One limitation of our trial design is reliance on there being a sig
nificant prevalence of patients with hs-cTnI ≤5 ng/L and reliance on
clinician adherence to the RACE-IT protocol for these patients. While
our preliminary data estimates that approximately 40% of eligible pa
tients will fall in this group, it could be smaller and negatively impact
the trial’s statistical power. The estimated 60% of patients with a hs-cTnI
of 6–18 ng/L are included in the trial but have similar clinical treatment
pathways in both the RACE-IT and SOC protocols. Poor clinical adher
ence to the protocol, particularly for patients with hs-cTnI values ≤ 5
ng/L will also impact statistical power and bias results towards the null
hypothesis.
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5. Conclusion
Accurately and efficiently evaluating ACS in the ED has significant
implications for patient outcomes and health system operations. The
thoughtful implementation of hs-cTn assays have great potential to more
quickly rule-out ACS while preserving patient safety and reducing hos
pital resource utilization. This trial utilizes a modified stepped wedge
cluster randomized design to evaluate these potential benefits in a large
health system operating nine EDs that could have significant implica
tions for other sites around the world considering similar protocols.
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